Skip to main content

Table 4 Univariate and multivariable logistic regression analysis for 30-day mortality

From: Prevalence and impact of early prone position on 30-day mortality in mechanically ventilated patients with COVID-19: a nationwide cohort study

 

Univariate

Multivariable

OR (95% CI)

P value

OR (95% CI)

P value

Prone

    

Early = no

Reference

 

Reference

 

Early = yes

0.86 (0.69—1.08)

0.2035

0.92 (0.71—1.19)

0.5206

Sex

    

Women

Reference

 

Reference

 

Men

1.33 (1.05—1.68)

0.0183

1.28 (0.99—1.67)

0.0645

Age, per year

1.07 (1.06—1.09)

 < 0.001

1.07 (1.06—1.09)

 < 0.001

Comorbidity

    

Cardiac disease

1.93 (1.46—2.56)

 < 0.001

1.14 (0.83—1.57)

0.4203

COPD/Asthma

1.08 (0.81—1.43)

0.5844

1.15 (0.84—1.56)

0.3846

Diabetes

1.22 (0.97—1.54)

0.0807

1.12 (0.86—1.45)

0.4021

Obesitya

0.63 (0.43—0.89)

0.0122

1.15 (0.76—1.72)

0.4979

Hypertension

1.33 (1.08—1.64)

0.0071

0.86 (0.67—1.10)

0.2276

Immune deficiency

1.52 (1.04—2.19)

0.0271

1.60 (1.05—2.42)

0.0279

Chronic liver disease

0.81 (0.18—2.72)

0.7502

0.57 (0.11—2.33)

0.4637

Chronic kidney disease

1.61 (1.05—2.44)

0.0268

1.05 (0.65—1.66)

0.8535

Neuromuscular disease

0.69 (0.20—1.94)

0.5167

0.62 (0.17—1.92)

0.4384

Malignancyb

3.02 (1.48—6.26)

0.0025

2.12 (0.97—4.69)

0.0585

PaO2/FiO2 ratio, per 1 kPa increase

0.97 (0.94—1)

0.0370

0.98 (0.95 – 1.02)

0.3362

SAPS3c, per 1 unit increase

1.05 (1.04—1.07)

 < 0.001

1.05 (1.04—1.07)

 < 0.001

Admission months

    

March – April 2020

Reference

 

Reference

 

May – August 2020

0.57 (0.39—0.83)

0.0037

0.45 (0.30—0.68

 < 0.001

September – December 2020

1.19 (0.88—1.60)

0.2489

0.80 (0.57—1.11)

0.1848

January – April 2021

0.91 (0.71—1.18)

0.4793

0.62 (0.46—0.83)

0.0014

  1. OR, Odds Ratio; CI, Confidence Interval; COPD, chronic obstructive pulmonary disease; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SAPS, simplified acute physiology score
  2. aObesity defined as BMI > 40 kg/m2
  3. bMalignancy is defined as neoplasia spread beyond regional lymph nodes
  4. cRecalculated after excluding age, comorbidities and PaO2/FiO2 ratio
  5. aROC 0.749 for full model